---
layout: default
title: Activated Charcoal Araneus Diadematus Arsenic Trii
parent: 僅模型預測 (L5)
nav_order: 197
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Araneus Diadematus Arsenic Trii
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Formula: Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This submission contains a 25-ingredient homeopathic/botanical combination formula (including activated charcoal, plant extracts, mineral salts, and biological venoms). The TxGNN model was unable to generate any repurposing predictions for this entry, and the formula has no regulatory approval in the United States. Without predicted indications, original approved indications, or mechanism-of-action data, a standard repurposing evaluation cannot be conducted at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and even that is absent) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No prediction was generated, so this section describes why the analysis stalled.

The submitted entry is a 25-component mixture containing heterogeneous ingredient classes: adsorbents (activated charcoal), botanical whole-plant preparations (Echinacea, Baptisia, Lobelia, Phytolacca, Thuja, etc.), mineral salts (cupric sulfate, manganese chloride, potassium chloride, zinc gluconate), biological venoms (Lachesis muta venom, Araneus diadematus), and a fruit extract (Rosa canina). This degree of compositional complexity is incompatible with TxGNN's standard drug-node representation, which maps single chemical entities to a knowledge graph. Because no single DrugBank ID could be assigned, the model had no anchor from which to traverse the knowledge graph and generate disease predictions.

Mechanism-of-action data is unavailable for the combination as a whole. Individual ingredients such as capsicum (transient receptor potential channel modulation), zinc gluconate (immune modulation), and echinacea (innate immune stimulation) have documented individual mechanisms, but these cannot be aggregated into a coherent MOA profile for the mixture without dedicated pharmacological characterisation.

From a regulatory standpoint, multi-ingredient homeopathic products of this type are typically evaluated under a different evidentiary framework than conventional pharmaceuticals, and none of the 25 named ingredients in this specific combination appear to hold a US NDA or equivalent approval record in this formulation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this specific multi-component combination formula.

---

## Literature Evidence

Currently no related literature available for this specific combination as an entity. Individual ingredients (e.g., Echinacea, zinc, activated charcoal) have independent literature bodies, but these cannot be attributed to the combination without dedicated studies.

---

## US Market Information

This formula has no US regulatory authorizations on record.

---

## Safety Considerations

Please refer to the package insert for safety information. The following observations are noted based on known ingredient-level concerns:

- **Arsenic Triiodide**: Even in homeopathic dilutions, arsenic compounds warrant documentation of preparation dilution factor and confirmation that the final product falls below toxicological threshold concentrations.
- **Lachesis muta venom**: A potent anticoagulant and cytotoxic biological substance; dilution verification is essential.
- **Lobelia inflata**: Contains lobeline; toxic in non-homeopathic doses with a narrow therapeutic window.
- **Drug Interactions**: No DDI data found in the queried database for this combination.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This formula cannot proceed through a standard TxGNN repurposing pipeline because it lacks a single DrugBank-mappable entity, has no approved indications as a reference point, and produced no TxGNN predictions. The data gaps are structurally blocking rather than merely supplementary.

**To proceed, the following is needed:**

- **Decompose the combination**: Submit each of the 25 ingredients as individual TxGNN queries to identify which components, if any, have repurposing signal.
- **Establish a canonical formulation identity**: Assign a product-level identifier (e.g., a homeopathic pharmacopoeial monograph number or NDC code) to anchor regulatory and safety lookups.
- **Obtain dilution/concentration data**: For safety-critical ingredients (arsenic triiodide, Lachesis venom, Lobelia), confirm the preparation dilution factor (e.g., 6C, 30X) to determine whether standard toxicological thresholds apply.
- **Retrieve package insert**: Download the product label PDF to extract intended use, contraindications, and any existing warnings.
- **Clarify intended therapeutic claim**: Determine whether this product is positioned as a homeopathic remedy (symptom-based labelling) or a conventional fixed-dose combination — this determines which regulatory and evidentiary pathway applies.
- **Re-run TxGNN at ingredient level**: Once individual DrugBank IDs are confirmed for mappable ingredients (e.g., activated charcoal → DB01002, capsaicin → DB06774, zinc gluconate → DB14533), generate per-ingredient predictions and assess combinatorial plausibility.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

